Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

German “Wondergel” for Arthritis goes Global
  • USA - English


News provided by

Pro Bono Bio

Oct 25, 2013, 04:00 ET

Share this article

Share toX

Share this article

Share toX

"Wonder Gel"
"Wonder Gel"

I actually have arthritis in a lot of my joints. My movement would be restricted but since I started using FLEXISEQ, I am actually walking better. I use it on my knees and on my shoulder as well.

Post this

Berlin, Germany (PRWEB UK) 25 October 2013 -- The International success of the breakthrough German therapy for osteoarthritis, FLEXISEQ™, was reported at a Healthcare Congress in Berlin today. FLEXISEQ is a safe*, effective and drug-free alternative in the treatment of osteoarthritis pain and joint stiffness. FLEXISEQ was reported as being nicknamed a “Wondergel” by patients and the press across the test markets in Europe. The gel contains no pharmacologically active substances, but works through the use of Sequessome™ vesicles, tiny phospholipid spheres that penetrate the skin, into the joint and lubricate the damaged cartilage. FLEXISEQ has already received the Innovation Award 2013 from the Federal Association of German Pharmacists for its innovative Sequessome Technology®.

Huge Need for a New Therapy

The President of the Hessen Rheumatism League, Dr. Wolfgang Bolten, knows the problems of patients with joint pain first-hand. “Pain therapy in particular is discussed in self-help groups”, he says. “Which anti-inflammatory drug works best? Which of them has the lowest rate of side effects? What other alternatives are available? One important topic in the discussion is the long-term safety of the analgesic medication they are using. Analgesics such as paracetamol, non-steroidal anti-inflammatory drugs (NSAIDs) and opioids are the standard treatment. Reading the package leaflet or listening to patient experiences however, gives an idea of the risk some patients are taking if they have to use these medications over long periods of time."

“NSAIDs have fallen into disrepute of late. A warning about diclofenac was recently issued by the European Medicines Agency due to the risk of side effects for the elderly and for those patients already being treated for diseases of the circulatory system, kidneys or the gastro-intestinal tract. On the other hand, the elderly suffer increased pain from wear on their joints. They urgently need a safe and side effect-free treatment for their complaints. FLEXISEQ meets this need for many patients.”

FLEXISEQ Improves Patients’ Lives

In every country where FLEXISEQ is available, there have been reports by satisfied patients about their progress.

In Germany, Michaela R., mother of four and an active athlete, said, “FLEXISEQ has helped me a lot. I am really happy to be able to do sport again, and am happy to recommend FLEXISEQ.”

In Ireland, Emer O’Hanlon said, “FLEXISEQ has given me a new lease of life. I can play golf again, as well as play the piano for the first time in years. I am thrilled I’m back playing both again.”

In Ireland, 54-year-old housewife Jodie H. said, “I actually have arthritis in a lot of my joints. My movement would be restricted but since I started using FLEXISEQ, I am actually walking better. I use it on my knees and on my shoulder as well.”

In Austria, Otmar S., 73, is happy he can finally go walking again. “FLEXISEQ already helped me after the second application - the pain in my joints got better. I have no real problems anymore. I have tried other things, but nothing really helped, not even tablets.”

In Germany Mrs. W., 65, can now enjoy her garden again: “I felt pain in my left knee from garden work. After ten days of using FLEXISEQ, the pain noticeably decreased. The gel helps in the morning and evening; I am no longer in pain when I get up and at night I can sleep well. I have tried out many things, but FLEXISEQ has helped me!“

Research conducted by Feierabend.de reported that 97% of users stated that FLEXISEQ was better or equal to other established medicines in reducing their pain.

"Like a Cushion for Joints"

Even Toni “Twinpack” Polster, legendary footballer, uses it for his father’s osteoarthritis. He knows that even footballers and other athletes are particularly affected by joint wear and tear. His father uses FLEXISEQ with great success. “My father can finally walk well again,” says Polster, and he finds, “The gel suits me; it's like a cushion for my joints!“

Experts Report: FLEXISEQ Was Comprehensively Tested and Proven in the Clinic

Dr. Matthias Rother, in his speech about the clinical trial into the new gel, of which he was the co-creator, indicated that the effect of FLEXISEQ is comparable to conventional osteoarthritis medications. A comprehensive clinical programme has proven the good efficacy of the medical product FLEXISEQ. In a key comparative study with celecoxib, pain relief was already achieved after two days. The study showed that twice-daily application of FLEXISEQ leads to less pain and stiffness and better joint functioning, and this just as effectively as the twice daily intake of 100 mg celecoxib, an NSAID frequently used for chronic pain.

Dr. Werner Kneer, an orthopaedist and orthopaedic surgeon in private practice from Stockach, who also participated in the clinical trials for FLEXISEQ, submitted several case studies of patients who found relief with the innovative gel. Their night pain disappeared and joint mobility measurably increased. Prof. Dr. Egbert Johannes Seidel from the Centre for Physical and Rehabilitative Medicine at the Sophien- und Hufeland-Klinik Weimar GmbH also reported similar success. Since pain therapy is one of his specialties, he welcomes the expansion of the therapeutic options that FLEXISEQ provides.

German Success Stories

FLEXISEQ is a product of German Nanophysics Science. It was researched, developed and manufactured in Germany. Many of the excellent clinical trials were led by German physicians and involved German patients. FLEXISEQ is today exclusively manufactured in Germany. The new export markets (Turkey and Singapore launch next week) create jobs and drive royalty revenue into Germany. The new products that Sequessome™ vesicles can create are being developed in Germany. This official launch of Germany will hopefully lead to significantly more sales in Germany and yet more German jobs and taxation contribution. Despite all of this, the greatest success story is for those German patients benefiting from drug free, yet effective, pain relief from osteoarthritis. Ask your pharmacist for FLEXISEQ by name.

Some International Press Headlines

"Gel to wipe out Arthritic pain" - London Daily Express.
"Wondergel saved me from Chronic Pain" - Dublin Sunday World.
"Gel gives hope to 450,000 who suffer crippling pain of Arthritis" - Irish Independent.
"Arthritis sufferers in fight for "Wondergel" - Irish Mirror

  • In clinical trials, there were no health issues associated with long-term use of FLEXISEQ. Sequessome constituents that lubricate the joints are designated as GRAS (Generally Recognised As Safe) by the US FDA.

Martyn Smith, Pro Bono Bio, +44 2072915491, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.